Vascular effects of eplerenone in coronary artery disease with preserved ejection fraction: a double-blind, randomized, placebo-controlled trial by Sudano, Isabella et al.








Vascular effects of eplerenone in coronary artery disease with preserved
ejection fraction: a double-blind, randomized, placebo-controlled trial
Sudano, Isabella ; Naegele, Matthias ; Roas, Susanne ; Périat, Daniel ; Frank, Michelle ; Kouroedov,
Alexey ; Noll, Georg ; Lüscher, Thomas F ; Enseleit, Frank ; Ruschitzka, Frank ; Flammer, Andreas J
Abstract: BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) reduce morbidity and mor-
tality in heart failure with reduced ejection fraction (HFrEF). Their role in patients without heart failure,
particularly in patients with coronary artery disease (CAD) and preserved EF, is still a matter of debate.
HYPOTHESIS: The MRA eplerenone on top of standard medical therapy improves endothelial dys-
function and other markers of vascular health in CAD patients with preserved EF. METHODS: In this
double-blind, randomized, placebo-controlled study, 42 patients (mean age: 63.5 ± 9.1 years; 37 males)
were randomized to 4-week treatment with eplerenone 25 mg daily or placebo. The primary endpoint was
difference in endothelial function as assessed by flow-mediated dilatation (FMD) of the brachial artery.
Secondary endpoints included 24-hour blood pressure (BP), endothelial progenitor cells, and platelet
adhesion. RESULTS: No difference in the primary endpoint FMD was noted after 4 weeks of treatment
with eplerenone compared with placebo (FMD: 4.7% ± 2.0% and 4.9% ± 2.1%, respectively; P = 0.77).
There were no significant differences between eplerenone and placebo in 24-hour BP (mean systolic BP:
126.9 ± 17.3 and 123.3 ± 9.7 mm Hg, P = 0.41; diastolic BP: 73.3 ± 12.9 and 72.0 ± 7.5 mm Hg,
respectively, P = 0.69), number of endothelial progenitor cells, and platelet adhesion. CONCLUSIONS:
Adding low-dose eplerenone to standard medical therapy did not improve important markers of vascular
health in patients with CAD and preserved EF. Our results may help understand conflicting evidence
from larger clinical trials on MRAs in patients with preserved EF.
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Background: Mineralocorticoid receptor antagonists (MRAs) reduce morbidity and mortality in heart failure
with reduced ejection fraction (HFrEF). Their role in patients without heart failure, particularly in patients with
coronary artery disease (CAD) and preserved EF, is still a matter of debate.
Hypothesis: The MRA eplerenone on top of standard medical therapy improves endothelial dysfunction and
other markers of vascular health in CAD patients with preserved EF.
Methods: In this double-blind, randomized, placebo-controlled study, 42patients (meanage: 63.5± 9.1 years;
37males) were randomized to 4-week treatment with eplerenone 25mg daily or placebo. The primary endpoint
was difference in endothelial function as assessed by flow-mediated dilatation (FMD) of the brachial artery.
Secondaryendpoints included24-hourbloodpressure (BP), endothelial progenitor cells, andplatelet adhesion.
Results: No difference in the primary endpoint FMD was noted after 4 weeks of treatment with eplerenone
comparedwith placebo (FMD: 4.7%± 2.0%and4.9%± 2.1%, respectively;P= 0.77). Therewere no significant
differences between eplerenone and placebo in 24-hour BP (mean systolic BP: 126.9± 17.3 and 123.3± 9.7mm
Hg, P = 0.41; diastolic BP: 73.3± 12.9 and 72.0± 7.5mm Hg, respectively, P = 0.69), number of endothelial
progenitor cells, and platelet adhesion.
Conclusions: Adding low-dose eplerenone to standard medical therapy did not improve important markers of
vascular health in patients with CAD and preserved EF. Our results may help understand conflicting evidence
from larger clinical trials on MRAs in patients with preserved EF.
Introduction
Mineralocorticoid receptor (MR) antagonism has become
a main treatment paradigm in heart failure with reduced
ejection fraction (HFrEF). Two MR antagonists (MRAs),
spironolactone and eplerenone, have been shown to reduce
all-cause mortality and heart failure (HF) hospitalizations
in HFrEF, with class IA recommendations supporting their
use according to current guidelines.1,2 Though the benefit
of MR blockade in HFrEF is firmly established, its role in
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patients with coronary artery disease (CAD) with preserved
ejection fraction (EF) still remains a matter of debate.3
Interestingly, plasma aldosterone levels predict long-term
clinical outcome not only in HF,4 but also in CAD.5 Indeed,
aldosterone exerts multiple deleterious effects, particularly
salt and water retention, ventricular hypertrophy, myocar-
dial fibrosis, and endothelial dysfunction.6,7 Endothelial
dysfunction plays an important role in the pathogenesis of
CAD and is a well-established marker for cardiovascular
risk and prognosis.8 Accordingly, MR blockade has been
shown to improve endothelial dysfunction in patients with
HFrEF.9 It was the aim of the present study to prospectively
evaluate the effects of MR antagonism with eplerenone on
vascular health in CAD patients with preserved EF.
Methods
This trial included 42 patients with a history of CAD,
documented by coronary angiography, nuclear imaging,
or positive stress testing. Other inclusion criteria were
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age >30 years and stable cardiovascular medication for
≥4 months. Female patients needed to be postmenopausal.
Exclusion criteria were as follows: recent myocardial infarc-
tion, unstable angina, stroke, or any coronary interventions
within 3 months prior to study entry; uncontrolled arterial
hypertension (>160/90 mm Hg), any HF symptoms New
York Heart Association class I or higher; left ventricular
EF <50%; renal insufficiency (Cockcroft-Gault estimated
creatinine clearance <50 mL/min); insulin-dependent
diabetes mellitus; anemia (hemoglobin <10 g/dL); any
conditions associated with chronic infection or inflam-
mation; any malignancy; the presence of endocrine
disorders (Cushing disease, Addison disease, thyroid
dysfunction); and concomitant use of long-acting nitrates,
potassium supplements, potassium-sparing diuretics
(amiloride, eplerenone, spironolactone, or triamterene),
strong cytochrome P450 3A4 inhibitors (eg, ketoconazole,
itraconazole), and smoking.
Patients were recruited at the Cardiology Clinic at
the University Hospital Zurich, Switzerland. Informed
consent was obtained from and signed by all participants.
The study was approved by the local ethics committee
(Regulatory No. 1033) and was done in accordance with
the Declaration of Helsinki. The trial was registered at
http://www.ClinicalTrials.gov (NCT00427284).
After clinical examination, including measurement of
blood pressure (BP) and body weight, endothelial function
measurement was performed and blood samples were
drawn and processed immediately. The participants were
randomized in a double-blind fashion to receive eplerenone
25 mg once daily or matched placebo for 4 weeks on top
of current standard medical therapy. The low dose was
chosen to allow for assessment of BP-independent effects.
Randomization and blinding of study drugs was provided by
InterCorNet and the Cantonal Pharmacy (both in Zurich,
Switzerland). All investigators were unaware of the alloca-
tion procedure at any time. Measurements were performed
at baseline (time of randomization) and after 2 and 4 weeks
of daily intake of the study drug or placebo, respectively.
All patients were instructed to fast for ≥12 hours and
refrain from caffeine-containing products for ≥24 hours
prior to their appointments. The patients were advised not
to take their usual drugs in the morning of the examination
day. Measurement of flow mediated-vasodilatation (FMD)
and collection of blood samples was always done at rest, in
the morning, and in a quiet, air-conditioned room. Endothe-
lial function was assessed by measuring FMD of the brachial
artery, as described previously.10 In brief, the left brachial
artery was visualized 2 to 10 cm above the elbow with a
10-Mhz ultrasound system (Siemens X300; Siemens Switzer-
land AG, Zurich, Switzerland) using a stereotactic clamp and
a video processing system (FMD Studio, Pisa, Italy).11 One
minute after acquisition of the baseline diameter, a wrist
cuff was inflated to 220 mm Hg for 5 minutes. Immediately
after release, arterial diameter was continuously recorded.
Endothelial-independent vasodilatation was measured after
sublingual application of 0.4 mg glyceryl trinitrate (Nitrolin-
gual Spray; Pohl-Boskamp, Hohenlockstedt, Germany).
For measurement of endothelial progenitor cells (EPCs),
blood was collected and centrifuged at 1800 g for 30 minutes
within 1 to 2 hours. The buffy layer was transferred to
sterile centrifuge tubes. Mononuclear cells were washed
twice with 15 mL phosphate-buffered saline and seeded
on fibronectin-coated Lab-Tek Chamber Slides (Lab-Tek,
Wiesbaden, Germany) at a density of 2 million per well in 20%
fetal calf serum (FCS; Gibco, Invitrogen, Basel, Switzerland)
endothelial cell growth medium (EGM)-2 (Clonetics, Lonza,
Verviers, Belgium). The medium was changed after 3 days.
The cultures were analyzed at the fourth day of plating.
Adherent cells were incubated with 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine (DiI)-labeled acetylated low-
density lipoprotein (acLDL; Molecular Probes, Eugene,
Oregon, USA) and FITC-labeled Ulex europaeus agglutinin
(UEA)-I (Sigma-Aldrich, Steinheim, Germany) for 1 hour
and nuclei were stained with DAPI (4′,6-diamidino-2-
phenylindole; Sigma-Aldrich, Steinheim, Germany). Cells
were visualized with an inverted fluorescent microscope in
3 different visual fields. The LDL/agglutinin double-positive
cells were counted and considered as EPCs.
Ambulatory BP measurements were obtained over 24
hours using a Tracker NIBP 2 device under the study
medication (Del Mar Reynolds Medical, Hertford, United
Kingdom). Shear-stress-dependent platelet adhesion was
assessed using a cone and platelet analyzer as described
previously.12 Results are expressed as the percentage of
surface covered by platelets.
The difference in FMD was defined as the primary
endpoint. A FMD  of 1.5% and SD of 1.5% for eplerenone
vs placebo at 4 weeks was hypothesized. For a significance
level of 5%, 20 patients per treatment group were assumed
to be needed to reach a statistical power of ≥80%. The data
were checked for normal distribution. Normally distributed
data were expressed as mean ± SD. Non–normally dis-
tributed data were expressed as median and interquartile
range (IQR). A P value <0.05 was considered statistically
significant. ANOVA was used to assess intragroup as well
as intergroup differences at any time points for FMD. The
rest of the data were analyzed by paired and unpaired
Student t test and the Wilcoxon test, as appropriate. All
tests were 2-sided and analysis was per protocol. Statistical
analyses were performed using JMP version 9.0.1 (SAS
Institute Inc., Cary, NC).
Results
A total of 42 patients (21 per group; mean age,
63.5 ± 9.1 years; 37 male; mean body mass index
27.1 ± 3.5 kg/m2) were included in the study. Their clinical
characteristics and medications are presented in Table 1.
Both study groups were well matched with no significant
differences in baseline characteristics.
No adverse effects were noted during the duration of
the study. Baseline levels and changes of the primary and
secondary endpoints are shown in Table 2. The primary
endpoint FMD showed no significant difference between
eplerenone and placebo after 4 weeks of treatment (FMD:
4.7% ± 2.0% and 4.9% ± 2.1%, respectively; P = 0.77; Table 2
and Figure 1, part A). Consistency of the measurement was
verified using endothelium-independent vasodilatation after
glyceryl trinitrate, which showed no significant differences.
In regard to laboratory and hemodynamic parameters,
no significant differences in pro-brain natriuretic peptide,
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n= 21 P Value
Clinical characteristics
LVEF, % 61.1± 6.8 61.8± 7.0 0.75
BMI, kg/m2 27.6± 3.2 26.6± 3.7 0.35
Office SBP, mm Hg 129.9± 9.6 133.0± 13.5 0.39
Office DBP, mm Hg 79.5± 8.5 79.0± 8.7 0.83
Heart rate, bpm 58.8± 9.3 59.9± 8.2 0.69
Comorbidities
History of smoking 11 (52) 11 (55) 0.87
Dyslipidemia 19 (90) 18 (86) 0.63
HTN 14 (67) 13 (62) 0.75
DM 0 (0) 0 (0) —
History of MI 16 (76) 15 (71) 0.40
Family history for CAD 15 (79) 12 (67) 0.40
CV risk factors 3.5± 1.0 3.0± 1.0 0.11
Concomitant drug therapy
ASA 19 (90) 21 (100) 0.09
Clopidogrel 10 (48) 4 (19) 0.05
ACEI and/or ARB 12 (57) 14 (67) 0.53
β-Blocker 14 (67) 15 (71) 0.74
CCB 5 (24) 4 (19) 0.71
Diuretic 3 (14) 5 (24) 0.43
Statin 19 (90) 21 (100) 0.09
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB,
angiotensin receptor blocker; ASA, aspirin; BMI, body mass index;
CAD, coronary artery disease; CCB, calcium channel blocker; CV,
cardiovascular; DBP, diastolic blood pressure; DM, diabetes mellitus;
HR,heart rate;HTN,hypertension; LVEF, left ventricularejection fraction;
MI, myocardial infarction; SBP, systolic blood pressure; SD, standard
deviation.
Values are presented as n (%) or mean±SD.
potassium levels, high-sensitivity C-reactive protein, as
well as ambulatory and office BP and heart rate were
seen between both groups (Table 2). There was no
significant difference in the number of circulating EPCs
after treatment with eplerenone compared with placebo (1.3
[IQR, 1–4.5] and 1.7 [IQR, 0.8–2.4], respectively; P = 0.62).
Likewise, no significant differences in platelet adhesion were
seen between eplerenone and placebo (adhering platelets:
3.9% ± 1.6% and 4.1% ± 2.3%, respectively; P = 0.83).
A subgroup analysis showed that in patients with con-
current use of diuretic drugs (n = 3, all thiazide diuretics),
eplerenone significantly improved FMD, whereas it showed
no significant benefit in patients not taking diuretics (mean
FMD increase 2.57% ± 1.37% in patients taking diuretics;
mean change −0.45% ± 2.36% in patients not taking diuret-
ics; P = 0.049; Figure 1, part B). Potassium serum levels and
BP were not different in patients taking diuretics compared
with patients without diuretics, and no differences between
diuretic users and nonusers were seen in the placebo group.
Discussion
In this randomized, placebo-controlled trial, a 4-week
treatment with 25 mg eplerenone daily did not improve
endothelial function as assessed by FMD or affect 24-hour
BP, EPC numbers, and platelet adhesion in patients with
stable CAD and preserved EF.
There are several potential explanations for our findings.
First, renin-angiotensin-aldosterone system (RAAS) activa-
tion may not be pronounced enough in our specific subset of
CAD patients with preserved EF to benefit from MR block-
ade. Our study excluded patients with significant renal
insufficiency, HF, and uncontrolled hypertension, all con-
ditions known to result in increased RAAS activation. Our
patients were also well treated in regard to BP, and most
were concomitantly treated with an angiotensin-converting
enzyme inhibitor (ACEI), angiotensin receptor blocker
(ARB), or a statin, all drugs that can improve endothelial
dysfunction.13,14 With these prerequisites, eplerenone may
not have been able to further improve vascular function.
Interestingly, in the small subgroup of patients treated with
thiazide diuretics, eplerenone significantly improved FMD,
whereas no effect was seen in patients without concomitant
diuretic treatment. These results suggest that although MR
antagonists may not be helpful in all patients with CAD and
preserved EF, they may be useful in specific subgroups.
In the subgroup of thiazide diuretic users, MR antagonists
may counteract the potassium-wasting and RAAS-activating
effects of thiazide diuretics, resulting in a restoration of
body potassium levels and thereby beneficial vascular and
metabolic effects.15 This is in line with previous clinical
findings indicating that MR blockade is particularly effec-
tive when used in combination with diuretics.16 Similar
results were seen with potassium-sparing diuretics, which
prevented thiazide diuretic–induced glucose intolerance
while improving BP control in a recent trial.17
Second, MR antagonism may be beneficial in CAD, but
the effect is not mediated by an improvement in peripheral
endothelial dysfunction, but rather by local cardiomyocyte-
specific effects. The activation of MR on cardiomyocytes
can trigger coronary endothelial dysfunction by paracrine
factors, oxidative stress in particular.18 Indeed, specific MR
deletion in cardiomyocytes of mice led to infarct healing
and prevented cardiovascular remodeling,19 an effect not
seen by deletion of MR receptors on other cells.20 Direct
assessment of the coronary vasculature and myocardial
microcirculation may yield more positive results, and new
compounds, such as more selective MR antagonists, may
be helpful in delineating the differential effects of MR
antagonists on the heart and the vasculature.
A third explanation for our findings is that MR blockade
is not beneficial in CAD patients with preserved EF.
Indeed, recent large randomized controlled trials have
yielded conflicting results with regard to MR blockade in
patients with a preserved EF. In the Impact of Eplerenone
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Table 2. Main Outcome Measures of the Trial
Parameters Eplerenone Baseline Eplerenone 4 Weeks Placebo Baseline Placebo 4 Weeks P Valuea
Endothelial function
FMD, % 4.6± 2.4 4.7± 2.0 5.1± 2.2 4.9± 2.1 0.77
GTN, % 12.4± 4.9 12.6± 5.7 13.8± 5.7 12.8± 12.8 0.90
Hemodynamic measures
24-hour SBP, mm Hg 128.1± 14.0 126.9± 17.3 124.1± 11.5 123.3± 9.7 0.41
24-hour DBP, mm Hg 75.3± 9.6 73.3± 12.9 72.5± 7.6 72.0± 7.5 0.69
24-hour heart rate, bpm 65.5± 9.7 66.8± 9.8 65.2± 7.6 66.3± 8.4 0.86
Office SBP, mm Hg 129.9± 9.6 126.2± 11.8 133.0± 13.5 127.5± 11.7 0.72
Office DBP, mm Hg 79.5± 8.5 75.6± 9.5 79.0± 8.7 77.1± 6.2 0.54
Heart rate, bpm 58.8± 9.3 58.3± 10.2 59.9± 8.2 60.4± 7.9 0.46
Laboratory parameters
Na, mmol/L 139.8± 2.4 139.4± 1.8 140.0± 1.7 140.0± 1.6 0.22
K, mmol/L 4.0± 0.3 4.0± 0.2 3.9± 0.3 3.9± 0.2 0.05
Cr, µmol/L 83.9± 11.0 92.1± 18.7 83.9± 11.0 84.5± 12.3 0.13
Glucose, mmol/L 5.5± 0.7 5.5± 0.8 5.3± 0.5 5.3± 0.9 0.53
proBNP, ng/L 142 (65.3–254.8) 119 (56–249.8) 129 (84.5–217.5) 110 (52.5–202.5) 0.41
hsCRP, mg/L 1.0 (0.4–3.3) 0.85 (0.43–2.4) 1.0 (0.6–1.2) 0.7 (0.6–1.5) 0.95
EPC, % 0.7 (0.5–1.7) 1.3 (1–4.5) 0.7 (0.4–1.3) 1.7 (0.8–2.4) 0.62
Platelet adhesion, % 3.9± 1.9 3.9± 1.6 3.9± 1.2 4.1± 2.3 0.83
Abbreviations: Cr, creatinine; DBP, diastolic blood pressure; EPC, endothelial progenitor cells; FMD, flow-mediated vasodilatation; GTN, glycerol
trinitrate–mediated vasodilatation; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range; K, potassium; Na, sodium; proBNP, pro-brain
natriuretic peptide; SBP, systolic blood pressure; SD, standard deviation.
Values are presented as mean±SD or median (IQR).
aDifference between intervention and control at 4 weeks.
on Cardiovascular Outcomes in Patients Post–Myocardial
Infarction (REMINDER) trial, myocardial infarction patients
without HF symptoms and with a preserved EF received
eplerenone or placebo for >1 year.21 Although the trial
met its primary composite endpoint, this observation was
largely mediated by a reduction in N-terminal pro-brain
natriuretic peptide levels, a component of the primary
endpoint, but not significantly by other more relevant
components such as HF hospitalizations and cardiovascular
mortality. In the Treatment of Preserved Cardiac Function
Heart Failure With an Aldosterone Antagonist (TOPCAT)
trial, spironolactone was tested in patients with heart
failure with preserved ejection fraction (HFpEF).3 Here,
spironolactone failed to reduce the composite primary
endpoint of cardiovascular death, aborted cardiac arrest,
and HF hospitalizations. Both studies stand in contrast
to the unequivocally positive results of MR antagonists
in HFrEF.1,2 Interestingly, MR blockers have been shown
to also improve endothelial function in HFrEF, paralleling
the benefit on hard endpoints.9,22 The reasons for these
diverging results remain elusive. One possibility may
be more pronounced RAAS activation in patients with
reduced compared with preserved EF, although clear
data on this is lacking. Regional or other phenotypic
differences may also play a decisive role. In a post-hoc
analysis of the TOPCAT trial, spironolactone significantly
reduced the primary endpoint in HFpEF patients from the
Americas, whereas it had no effect in HFpEF patients
from Eastern Europe.23 In light of these conflicting
results, a beneficial effect of MR antagonism in CAD
or HF patients with a preserved EF currently cannot be
excluded.
Study Limitations
The relatively low dose of eplerenone was chosen to allow
for an evaluation of BP-independent effects of the drug, as
lowering of BP itself is known to alter endothelial function.
Although similar doses of MR antagonists were used in the
large outcome trials, dose and duration of treatment may
at least in part account for the observed neutral effects
under the conditions of the present study. In patients
with untreated hypertension and no background therapy
with ACEIs or ARBs, and thus potentially higher RAAS
activation than in the present study, 50 mg eplerenone
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Figure 1. Effect of eplerenone on the primary endpoint FMD after 4 weeks of treatment compared with placebo (A). Subgroup analysis of change in FMD
from baseline to 4 weeks in the eplerenone group ( FMD), separated by concurrent use of diuretics (B). Abbreviations: FMD, flow-mediated vasodilatation.
daily did not improve endothelial function after 4 weeks
but after 12 and 48 weeks of treatment.24 It is possible
that longer treatment duration or a higher dose of MR
antagonists is necessary to see beneficial vascular effects
in CAD patients with preserved EF. Given the different
receptor specificities of currently available MR antagonists
and the lack of comparative studies, we also cannot rule
out that spironolactone has a different effect on endothelial
function compared with eplerenone.25 Finally, aldosterone
levels were not assessed in this study due to the concomitant
therapy with ACEIs, ARBs, and β-blockers. Correlation
between changes in aldosterone levels as a response
marker for MR antagonism and endothelial dysfunction
may yield additional valuable information in future
studies.
Conclusion
In summary, the MR antagonist eplerenone on top of
standard medical therapy failed to improve endothelial
function and other surrogate markers of cardiovascular
health in patients with CAD and preserved EF. Further
studies that focus on specific CAD subgroups such as
diuretic users, patients with significant hypertension, or
patients with chronic kidney disease may be helpful in
further elucidating whether MR blockade is helpful in this
patient population.
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